No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana.
Souda S, Gaseitsiwe S, Georgette N, Powis K, Moremedi D, Iketleng T, Leidner J, Moffat C, Ogwu A, Lockman S, Moyo S, Mmalane M, Musonda R, Makhema J, Essex M, Shapiro R.
Souda S, et al. Among authors: georgette n.
J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):572-7. doi: 10.1097/QAI.0b013e31829308f8.
J Acquir Immune Defic Syndr. 2013.
PMID: 23542639
Free PMC article.
Clinical Trial.